LSE:IRSH

Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc.

Friday, September 17, 2021 - 2:09pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc.

Tuesday, September 14, 2021 - 1:15pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Grand City Properties S.A.: Release of a capital market information

Monday, September 13, 2021 - 11:04am

5 Sec.

Key Points: 
  • 5 Sec.
  • 3 of the Commission Delegated Regulation (EU) No 2016/1052 - 26 Interim Announcement
    In the period from 6 September 2021 up to and including 10 September 2021, Grand City Properties S.A. bought back a total of 407,720 shares of Grand City Properties S.A. under the Share Buy-Back Programme 2021; on 15 March 2021, Grand City Properties S.A. disclosed pursuant to Art.
  • 1 of the Commission Delegated Regulation (EU) No 2016/1052 the beginning of the share buyback on 16 March 2021.
  • The overall volume of the shares bought back daily and the daily volume-weighted average stock market prices of the shares are as follows:

Grand City Properties S.A.: Release of a capital market information

Monday, September 6, 2021 - 12:38pm

5 Sec.

Key Points: 
  • 5 Sec.
  • 3 of the Commission Delegated Regulation (EU) No 2016/1052 - 25 Interim Announcement
    In the period from 30 August 2021 up to and including 3 September 2021, Grand City Properties S.A. bought back a total of 357,494 shares of Grand City Properties S.A. under the Share Buy-Back Programme 2021; on 15 March 2021, Grand City Properties S.A. disclosed pursuant to Art.
  • 1 of the Commission Delegated Regulation (EU) No 2016/1052 the beginning of the share buyback on 16 March 2021.
  • The overall volume of the shares bought back daily and the daily volume-weighted average stock market prices of the shares are as follows:

Grand City Properties S.A.: Release of a capital market information

Monday, August 30, 2021 - 10:02am

5 Sec.

Key Points: 
  • 5 Sec.
  • 3 of the Commission Delegated Regulation (EU) No 2016/1052 - 24 Interim Announcement
    In the period from 23 August 2021 up to and including 27 August 2021, Grand City Properties S.A. bought back a total of 258,167 shares of Grand City Properties S.A. under the Share Buy-Back Programme 2021; on 15 March 2021, Grand City Properties S.A. disclosed pursuant to Art.
  • 1 of the Commission Delegated Regulation (EU) No 2016/1052 the beginning of the share buyback on 16 March 2021.
  • The overall volume of the shares bought back daily and the daily volume-weighted average stock market prices of the shares are as follows:

Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc

Thursday, August 26, 2021 - 2:29pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Aroundtown announces H1 2021 results with additional successful disposals

Wednesday, August 25, 2021 - 6:12am

- Disposals of 1.1 billion completed in H1 2021 at 3% above book value, crystalizing total gains of 51% over total costs (including capex).

Key Points: 
  • - Disposals of 1.1 billion completed in H1 2021 at 3% above book value, crystalizing total gains of 51% over total costs (including capex).
  • - Adjusted EBITDA of 452 million for H1 2021, as compared to 500 million in H1 2020.
  • - FFO I of 172 million for H1 2021, as compared to 234 million for H1 2020, lower as a result of disposals and extraordinary expenses due to the covid pandemic.
  • - FFO I per share of 0.15 generated in H1 2021, as compared to 0.17 per share generated in H1 2020.